SITORSA®

Category

Oral antidiabetic

Drug class

Dipeptidyl Peptidase-4 (DPP-4) inhibitor

Indication

• Used in the management of Type 2 Diabetes Mellitus
• Helps improve blood sugar control when diet and exercise are not enough
• Can be used alone or in combination with other antidiabetic agents (e.g., metformin, sulfonylureas, SGLT2 inhibitors, insulin)

Mechanism of Action

• Inhibits the DPP-4 enzyme, which breaks down incretin hormones (GLP-1 and GIP)
• Increased incretin levels ? increased insulin release (glucose-dependent) and decreased glucagon secretion
• Results in lower fasting and postprandial blood glucose without significant risk of hypoglycemia when used alone

Dosage

• Usual adult dose: 100 mg orally once daily (with or without food)
• Renal impairment dose adjustment:
  • eGFR ?45 mL/min/1.73 m² ? No adjustment
  • eGFR 30–44 ? 50 mg once daily
  • eGFR <30 or on dialysis ? 25 mg once daily

Side Effects

• Rare but serious:
  • Pancreatitis (report abdominal pain immediately)
  • Hypersensitivity reactions (Stevens–Johnson syndrome, angioedema)
  • Severe joint pain (arthralgia)

Patient Advice

• Take at the same time daily for best results
• Can be taken with or without food
• Maintain healthy diet and exercise plan alongside medication
• Report symptoms of severe abdominal pain, skin rash, or swelling immediately